GCGR Overview
Molecule Name
Glucagon receptor
Synonyms
Glucagon R, GCGR,Glucagon receptor
Drug Development Progress
Drugs in Clinical Trials40
Approved Drugs6
Highest Development StageApproved
Target Synonym
GL-R，GCGR，Glucagon Receptor，GGR，Receptors， Glucagon
Background
The protein encoded by this gene is a glucagon receptor that is important in controlling blood glucose levels. Defects in this gene are a cause of type 2 diabetes mellitus (T2DM) . The ever increasing prevalence of type 2 diabetes mellitus in the developed and developing nations calls for the introduction of new and more effective treatments. Glucagon receptor (GCGR) antagonists are highly validated in preclinical models of T2DM and thus have the potential to be developed as a new therapy.
GCGR Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| PRT-001 | PRT-001 | Phase 3 Clinical | Particle Therapeutics | Hypoglycemia | Details |
| Retatrutide | LY-3437943 | Phase 3 Clinical | Eli Lilly And Company | Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hepatic Insufficiency; Insulin Resistance; Liver Diseases; Low Back Pain; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Osteoarthritis, Knee; Overweight; Renal Insufficiency; Renal Insufficiency, Chronic; Sleep Apnea, Obstructive | Details |
| Survodutide | BI-456906; BI-456909 | Phase 3 Clinical | Zealand Pharma A/S | Diabetes Mellitus; Diabetes Mellitus, Type 2; Fibrosis; Hepatitis; Liver Cirrhosis; Liver Diseases; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight; Renal Insufficiency; Renal Insufficiency, Chronic | Details |
| BioGlutide | NA-931 | Phase 3 Clinical | Biomed Industries Inc | Body Weight; Body Weight Changes; Diabetes Mellitus; Diabetes Mellitus, Type 2; Obesity; Overweight; Weight Loss | Details |
| Pemvidutide | ALT-801(Altimmune); SP-1373; VPD-107 | Phase 2 Clinical | Velocity Pharmaceutical Development | Alcoholism; Diabetes Mellitus, Type 2; Liver Diseases, Alcoholic; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight | Details |
| Efinopegdutide | JNJ-64565111; HM-12525A; JNJ-5111; MK-6024 | Phase 2 Clinical | Hanmi Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2; Hepatic Insufficiency; Kidney Failure, Chronic; Liver Diseases; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity | Details |
| Efocipegtrutide | HM-15211 | Phase 2 Clinical | Hanmi Pharmaceutical Co Ltd | Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity | Details |
| volagidemab | AMG-477; REMD-477 | Phase 2 Clinical | Amgen Inc | Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucose Intolerance; Hyperglycemia; Insulin Resistance; Iron deficiency | Details |
| Isosteviol | ISV; STX-03 | Phase 2 Clinical | Stevia Pharma | Diabetes Mellitus, Type 2 | Details |
| Glucagon | MP-123456B | Phase 2 Clinical | Eli Lilly And Company | Diabetes Mellitus; Diabetes Mellitus, Type 1; Hypoglycemia | Details |
| Oxyntomodulin long-acting (Pharmsynthez/Xenetic Biosciences) | Phase 2 Clinical | Pharmsynthez, Xenetic Biosciences Inc | Diabetes Mellitus, Type 2; Obesity | Details | |
| IONIS-GCGRRx | IONIS-GCGRRx; ISIS-449884; ISISGCGRRx | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Diabetes Mellitus, Type 2 | Details |
| Efpegerglucagon | HM-15136 | Phase 2 Clinical | Hanmi Pharmaceutical Co Ltd | Congenital Hyperinsulinism; Diabetes Mellitus, Type 2; Obesity | Details |
| UBT-251 | UBT251; UBT-251 | Phase 2 Clinical | Lianbang Biotechnology (Zhuhai Hengqin) Co Ltd | Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight; Renal Insufficiency; Renal Insufficiency, Chronic; Sleep Apnea, Obstructive | Details |
| AZD9550 | AZD9550; AZD-9550 | Phase 2 Clinical | Astrazeneca Plc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight | Details |
| MWN-109 | MWN-109 | Phase 2 Clinical | Shanghai Minwei Biotechnology Co Ltd | Body Weight; Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight | Details |
| MWN-101 | MWN-101 | Phase 2 Clinical | Shanghai Minwei Biotechnology Co Ltd | Diabetes Mellitus, Type 2; Obesity; Overweight; Sleep Apnea, Obstructive | Details |
| RBD-4988 | RBD-4988 | Phase 2 Clinical | Suzhou Ribo Life Science Co Ltd | Diabetes Mellitus, Type 2 | Details |
| ZX-2021 | ZX-2021; ZX2021 | Phase 2 Clinical | Jiangsu Zhongxin Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight | Details |
| DR-10624 | DR-10624; DR10624 | Phase 2 Clinical | Zhejiang Doer Biologics Corp | Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease; Metabolic Syndrome; Obesity; Overweight | Details |
| PB-718 | PB-718 | Phase 2 Clinical | Peg Bio Co Ltd | Congenital Hyperinsulinism; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight | Details |
| TB-001 | TB001; TB-001 | Phase 2 Clinical | Shenzhen Turier Biotech Co Ltd | Cholangitis, Sclerosing; Hepatitis B, Chronic; Liver Cirrhosis; Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
| DD-01 | DD-01 | Phase 2 Clinical | D&D Pharmatech | Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight | Details |
| Cotadutide | MEDI-0382 | Phase 2 Clinical | Medimmune Llc | Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Hepatic Insufficiency; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Renal Insufficiency; Renal Insufficiency, Chronic | Details |
| Glucagon (rDNA origin, Lilly) | Phase 1 Clinical | Eli Lilly And Company | Diabetes Mellitus, Type 1; Hypoglycemia; Insulin Resistance; Obesity | Details | |
| Glucagon (Translational Research Institute for Metabolism and Diabetes, Florida) | Phase 1 Clinical | Translational Research Institute For Metabolism And Diabetes | Obesity | Details | |
| Glucagon agonist (Imperial college London) | Phase 1 Clinical | Imperial College London | Obesity | Details | |
| glucagon (Therakind) | Phase 1 Clinical | Therakind Ltd | Hypoglycemia | Details | |
| PRT-003 | PRT-003 | Phase 1 Clinical | Particle Therapeutics | Details | |
| GGG Tri-Agonist III (Lilly) | Phase 1 Clinical | Eli Lilly And Company | Cardiovascular Diseases | Details | |
| DYX-116 | DYX116; DYX-116 | Phase 1 Clinical | Jiangsu Deyuan Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2; Obesity; Overweight | Details |
| KAI-4729 | HRS-4729; KAI-4729 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd | Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight | Details |
| XTL-6001 | XTL-6001; XTL6001 | Phase 1 Clinical | Shanghai Xizaili Biomedical Technology Co Ltd | Obesity; Overweight; Proteinuria; Renal Insufficiency, Chronic | Details |
| NN-6177 | NN-6177 | Phase 1 Clinical | Novo Nordisk A/S | Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
| Glucagon/insulin human(Abvance Therapeutics) | ABV-100 | Phase 1 Clinical | Abvance Therapeutics | Hypoglycemia | Details |
| PB-722 | PB722; PB-722 | Phase 1 Clinical | Peg Bio Co Ltd | Congenital Hyperinsulinism | Details |
| CMS-D005 | CMS-D005 | Phase 1 Clinical | China Medical System Holdings Ltd | Metabolic Diseases; Obesity; Overweight | Details |
| TY-751 | TY-751; TY751 | Phase 1 Clinical | Tianjin Remedy Research Institute | Diabetes Mellitus; Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight | Details |
| DA-1726 | DA-1726 | Phase 1 Clinical | Dong-A ST Co Ltd | Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity | Details |
| SHR-1816 | SHR1816; SHR-1816 | Phase 1 Clinical | Beijing Suncadia Medicine Co Ltd | Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Glucagon (rDNA origin, Novo Nordisk) | GL-G | Approved | Novo Nordisk A/S | GlucaGen, Glucagon G | Japan | Hypoglycemia | Novo Nordisk A/S | 1996-05-01 | Diabetes Mellitus, Type 1; Gastrointestinal Diseases; Hypoglycemia; Obesity | Details |
| Dasiglucagon | ZP-GA-1; ZP-4207 | Approved | Zealand Pharma A/S | Zegalogue | United States | Hypoglycemia | Zealand Pharma Us Inc | 2021-03-22 | Congenital Hyperinsulinism; Diabetes Mellitus; Diabetes Mellitus, Type 1; Glucose Metabolism Disorders; Hyperinsulinism; Hypoglycemia | Details |
| Mazdutide | OXM-3; IBI-362; LY-3305677 | Approved | Eli Lilly And Company | 信尔美 | Mainland China | Obesity; Overweight | Innovent Biologics(Suzhou) Co Ltd | 2025-06-24 | Alcoholism; Diabetes Mellitus, Type 2; Heart Failure; Heart Failure, Diastolic; Hypertension; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight; Renal Insufficiency; Sleep Apnea Syndromes; Sleep Apnea, Obstructive | Details |
| Glucagon intranasal (Eli Lilly/Locemia Solutions) | AMG504-1; LY-900018 | Approved | Amg Medical, Locemia Solutions | Baqsimi | United States | Hypoglycemia | Amphastar Pharmaceuticals Inc | 2019-07-24 | Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Hypoglycemia | Details |
| Glucagon (Xeris Pharmaceuticals) | Approved | Xeris Pharmaceuticals Inc | Gvoke, Ogluo, GVOKE VialDx | United States | Hypoglycemia | Xeris Pharmaceuticals Inc | 2019-09-10 | Hyperinsulinism; Hypoglycemia | Details | |
| Glucagon (Tetris) | Approved | Tetris Pharma Ltd | Ogluo | EU | Hypoglycemia | Tetris Pharma Ltd | 2021-02-11 | Hypoglycemia | Details |